VALARTH See Alkem Laboratories in the appOpen in app
ALKEM · NSE · Pharmaceuticals

Alkem Laboratories Ltd

What the numbers mean, from its filings and the exchange. Data as of 12 Oct 2026.
Mid Cap · AMFI list Jan-Jun 2026 · Vendor sector: Basic Materials
cheap low confidence No valuation within 120 days; P/E 29.3 vs peers 39.3 (4th of 23); P/B 4.5 vs peers 5.6 (11th of 25).
Cheap for a reason: A negative 5-year return.
Statements through FY2026Prices adjusted for corporate actionsNot yet reviewed by the adversarial model

What is Alkem Laboratories's share price today?

Alkem Laboratories last traded at ₹5,205.00 on the NSE, as of 12 Oct 2026, 11:00 pm IST, down 1.4% on the day, down 3.9% over a year. Its 52-week range is ₹5,051 to ₹5,934. The live price is in the app.

₹5,205.00 −1.4% today
−3.9% over 1 year · NSE, as of 12 Oct 2026, 11:00 pm IST
60 month-end closes, 31 Oct 2021 to 30 Sep 2026, adjusted for splits and bonuses
52-week range17% of the way up
Low ₹5,051High ₹5,934

What is Alkem Laboratories's market cap?

Alkem Laboratories's market capitalisation is about ₹63,118 crore: what it would cost to buy every share at today's price. That makes it the 67th largest mid cap company we cover.

₹63,118 Cr Mid Cap67th largest mid cap company
Mid Cap means the companies ranked 101 to 250 by size, under SEBI's rules. Shares in issue are worked out from the market cap and the price. What market cap tells you →

Key facts

From the exchange
Symbol
NSE: ALKEM
ISIN
INE540L01014
Cap bucket
Mid Cap, 67th largest by market cap
Industry (NSE)
Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
Listed since
2015
Futures and options
Traded

Is Alkem Laboratories overvalued?

Cheap, with low confidence: no valuation within 120 days; P/E 29.3 vs peers 39.3 (4th of 23); P/B 4.5 vs peers 5.6 (11th of 25). Cheap for a reason: A negative 5-year return.

Valuation

Latest price and trailing 12 months
P/E 29.26
vs peers 39.3 · 4th of 23
Price divided by last year's earnings per share: how many years of today's profit you pay for. Learn more →
P/B 4.53
vs peers 5.6 · 11th of 25
Price divided by book value per share: what you pay for each rupee of net assets on the balance sheet. Learn more →
Market cap ₹63,118 Cr
Total market value of all shares, in ₹ crore. Learn more →
Dividend yield 1.0%
vs peers 0.3% · 4th of 19
Last year's dividends as a share of today's price. Learn more →
PEG (vendor) Not available
P/E divided by the vendor's earnings growth figure, which it does not disclose; a P/E adjusted for how fast profits grow. Learn more →
PEG on our 3-year EPS growth 0.89
P/E divided by the 3-year EPS growth rate from the stored accounts. Learn more →
3 models could be judged
Skipped — Fair value, EPV, Graham number, Graham value, Lynch, Owner earnings: no valuation stored

Our valuation range

🔒 Pro
Value range, implied growth at today's price, and the nine models behind it: in the app.

Is Alkem Laboratories a quality business?

Quality score 55.7, 10th of 24 in its peer set; CAUTION on 30 of 30 flags judged.

Quality and risk

Data as of 12 Oct 2026
Business quality Not available
The kind of business, which sets the yardstick it is judged by. Learn more →
Quality score 55.7
vs peers 53.2 · 10th of 24
Returns, margins, leverage and consistency against its peers, out of 100. Learn more →
Risk level CAUTION
30 of 30 flags judged
From flags on debt, earnings quality, dilution and price swings. Learn more →

Profitability

ROE 17.3%
vs peers 15.2% · 11th of 25
Return on equity: profit as a share of shareholders' money. Learn more →
ROCE 18.8%
vs peers 17.9% · 12th of 25
Return on capital employed: operating profit as a share of all the capital in the business, debt and equity. Learn more →
Profit margin 13.8%
vs peers 13.8% · 13th of 24
Profit after everything, as a share of revenue. Learn more →
EPS ₹196.83
Trailing 12 months
Profit for each share over the last 12 months.

Scorecard

🔒 Pro
Health scores and red flags with their values and history: in the app.
See the scorecard →
Inside the app

Get a sneak peek of Valarth

Start freeStart free
A Valarth stock page: the share price with its chart and 52-week range, valuation and profitability figures, and a scorecard of health checks.
Stock pagePrice, valuation, profitability and a scorecard of health checks for every company, each figure explained.
The Valarth stock screener: a table of companies with price, market cap, P/E, P/B, PEG, EPS and ROE, and filters down the left.
ScreenerEvery listed company, filtered on 212 figures, each with a plain-language lesson beside it.
The Valarth AI Screener answering 'Which companies will benefit from India's Project 75 submarine programme?' with a basket of four naval shipbuilders and a written thesis.
AI ScreenerAsk a question in plain English, like which companies benefit from India's Project 75. It reads the intent, builds the screen and writes the thesis.
A Valarth business-model card for State Bank of India, with a plain-language summary and statements verified against the filing.
Business modelHow a company makes money and what can hurt it, each statement checked against its annual report.
Valarth's Before the Bell edition, with the day's headline, regulator notes and sector moves.
Before the BellA morning edition before the market opens: what moved, which rule changed, and what it means for your holdings.

Has Alkem Laboratories made money for shareholders?

Mixed: −3.9% over one year and +5.3% a year over five years.

Shareholder returns

1-year return −3.9%
Price only
What the share price did over the last 12 months. Learn more →
5-year return +5.3% a year
Price only
Yearly average price return over five years, bonuses and splits adjusted. Learn more →
Wealth destroyer Yes
Five-year total return — price CAGR on bonus- and split-adjusted closes plus the dividend yield — below the 7% a bank fixed deposit paid. Learn more →

Returns

3Y and 5Y are yearly averages
1W
+1.7%
1M
+2.3%
3M
−5.2%
6M
−1.6%
1Y
−3.9%
3Y
+11.5%
5Y
+5.3%

Does Alkem Laboratories pay a dividend?

Yes. Alkem Laboratories's dividend yield is 1.00% at the latest price; the last payout was ₹10.00 a share, ex-dividend 7 Aug 2026.

Dividends

Per share, by ex-dividend date
Dividend yield1.00%
The past 12 months' dividends as a share of today's price.
7 Aug 2026 · Final₹10.00
20 Feb 2026 · Interim₹43.00
8 Aug 2025 · Final₹8.00
14 Feb 2025 · Interim₹37.00
9 Aug 2024 · Final₹5.00
Payout ratio🔒 In the app
The share of profit paid out as dividends; a very high share leaves little to reinvest.
Dividend growth, 5 years🔒 In the app
How fast the dividend per share has grown a year.
Years without a miss🔒 In the app
How many years in a row a dividend has been paid.

Is Alkem Laboratories growing?

Revenue 3 years 9.0% a year; profit 3 years 32.7% a year; revenue 5 years 7.8% a year.

Growth

Statements through FY2026 (Mar-26)
Revenue 3 years 9.0% a year
vs peers 14.3% · 18th of 24
Compound annual growth of revenue over three years. Learn more →
Profit 3 years 32.7% a year
vs peers 20.2% · 7th of 21
Compound annual growth of net profit over three years. Learn more →
Revenue 5 years 7.8% a year
Compound annual growth of revenue over five years. Learn more →
Profit 5 years 5.6% a year
Compound annual growth of net profit over five years. Learn more →
EPS 3 years 32.7% a year
Growth in earnings per share, so dilution counts against the company. Learn more →
EPS 5 years 7.8% a year
Growth in earnings per share over five years, so dilution counts against the company. Learn more →
P/E vs own history -9.6%
vs peers 15.8% · 4th of 19
Today's P/E against its own 5-year median; negative is cheaper than its history. Learn more →

How did Alkem Laboratories do last quarter?

Alkem Laboratories reported revenue of ₹3,740 Cr, up 13.5% on a year earlier and a net profit of ₹521 Cr, up 6.2% in the Jun 2026 quarter.

Latest quarter

Jun 2026
Revenue, latest quarter₹3,740 Cr
+13.5% on a year earlier
What the company took in over the quarter.
Net profit, latest quarter₹521 Cr
+6.2% on a year earlier
What was left for shareholders after every cost and tax.

How does Alkem Laboratories compare with its peers?

Compared with 24 Pharmaceuticals; 4th of 23 on P/E; 10th of 24 on quality score.

Compared with 24 Pharmaceuticals

24 companies

Alkem Laboratories against its peers

Largest 10 of 24 peers, by market cap
CompanyMarket capP/EP/BROEROCE1YQuality 🔒Rank 🔒
Alkem Laboratories Ltd₹63,118 Cr29.34.517.3%18.8%−3.9%
Torrent Pharmaceuticals Ltd₹1.8 L Cr74.316.927.3%19.2%+32.4%
Zydus Lifesciences Ltd₹1.1 L Cr24.93.715.9%15.9%+12.3%
Laurus Labs Ltd₹1.1 L Cr100.510.215.1%14.9%+132.9%
Cipla Ltd₹1.1 L Cr31.22.910.6%13.9%−16.8%
Dr Reddys Laboratories Ltd₹99,911 Cr30.93.310.7%12.6%−5.2%
Mankind Pharma Ltd₹97,830 Cr47.95.013.3%13.1%−3.0%
Aurobindo Pharma Ltd₹97,411 Cr26.43.311.2%12.9%+48.9%
Lupin Ltd₹89,469 Cr15.83.523.4%27.5%−0.8%
Glenmark Pharmaceuticals Ltd₹64,714 Cr36.02.53.9%6.3%+20.1%
Biocon Ltd₹56,942 Cr102.82.20.9%1.6%—
Peer median—39.35.615.2%17.9%+33.8%
Market cap in rupees crore; P/E and P/B on the latest price; 1Y is the price return over a year. A dash is a figure that does not apply or is not reported.

Full peer comparison

🔒 Pro
Every peer, every figure, the ranks and the quality and forensic scores side by side: in the app.

Who owns Alkem Laboratories?

Alkem Laboratories is held by promoters 49.7%, foreign institutions 10.4%, domestic institutions 22.6%.

Shareholding pattern

Latest filing, percent of shares
Promoters49.7%
The founders and controlling group.
Foreign institutions10.4%
Overseas funds investing through the FPI route.
Domestic institutions22.6%
Indian insurers, banks, pension and mutual funds together.
Mutual funds16.7%
Indian mutual fund schemes; part of domestic institutions.
Retail and others1.1%
Individual investors and everyone else.
Promoter shares pledged🔒 In the app
Promoter shares given as collateral for loans; a high share is a risk to watch.
Holding trend🔒 In the app
Whether promoters, foreign funds and mutual funds have been adding or selling over recent quarters.

What do analysts say about Alkem Laboratories?

20 analysts cover Alkem Laboratories, and the consensus is buy. A consensus is a count of opinions, not a forecast; read it beside the numbers.

Analyst consensus

20 analysts
ConsensusBuy
The rating most covering analysts give the share.
Average target price🔒 In the app
The mean of the analysts' 12-month price targets.
Upside to target🔒 In the app
How far the target sits above or below today's price.
Share rating it a buy🔒 In the app
The share of covering analysts with a buy rating.

What does Alkem Laboratories do and what is it sensitive to?

Alkem Laboratories Limited sells pharmaceutical products, including chronic, specialty, OTC and generic lines, to pharmaceutical firms, distributors, wholesalers, pharmacy chains and hospitals in India, the US and more than 40 other countries. Sensitive to: indian Rupee exchange rate.

Business-model card

FY2026 · 49 verified
4Revenue
4Channels
4Regulators
5Reg. dependencies
6Sensitivities
5Costs
6Geographies

Alkem Laboratories Limited sells pharmaceutical products, including chronic, specialty, OTC and generic lines, to pharmaceutical firms, distributors, wholesalers, pharmacy chains and hospitals in India, the US and more than 40 other countries. Revenue is recognised net of discounts, schemes, chargebacks, rebates and returns, and the filings report that dealers and distributors account for most sales.

Revenue engine

4 verified
Revenue from India (by customer location)
Domestic revenue line in the segment note. Interpretation: this is the India business, which is also exposed to DPCO price controls. FY2026 ₹99,749.1 million; FY2025 ₹91,435.7 million.
Revenue from the United States
US revenue line in the segment note, reported by customer location. FY2026 ₹29,623.8 million; FY2025 ₹24,817.6 million.
Other International Markets revenue
Revenue from markets outside India and the US. The excerpt states growth of 8.7% YoY to ₹13,392 million in FY2025, with healthy growth in Australia and Europe. The segment note shows ₹17,749.8 million for FY2026.
1 more statement
Domestic portfolio medicines
Domestic medicines exposed to DPCO price controls. The company names chronic, specialty and OTC products as its mitigation, so these are the lines it is shifting toward.

Customers & channels

4 verified
Institutional and trade customers
The company names these as its customer groups. Interpretation: sales run through trade channels (distributors, wholesalers, pharmacy chains) as well as hospitals.
Dealer and distributor channel (98.1%)
Share of total sales made to dealers and distributors in FY2025. Interpretation: the channel is concentrated in trade partners rather than direct sales, and the number of dealers served was 8,799 in FY2025.
Wholesaler chargeback mechanism
Interpretation: wholesaler chargebacks reduce net realised price, so changes in wholesaler pricing terms move reported revenue. The excerpt states chargebacks are estimated from historical experience and contractual terms.
1 more statement
Hospital and institutional channel in Middle East
Excerpt names hospital and institutional channel expansion as the driver for Middle East markets; the excerpt does not say this is company revenue.

Regulators

4 verified
US Food and Drug Administration (USFDA)
Approves manufacturing facilities for the US market. Five of the company's 20 plants are USFDA-approved.
UK MHRA, EMA, TGA and WHO
Approvals held by the company's plants, which gate access to these markets.
National Pharmaceutical Pricing Authority (NPPA)
Sets price caps on products. The excerpt cites it for knee implants, which is a device category.
1 more statement
Drugs (Prices Control) Order, 2013 and National Pharmaceutical Pricing Policy, 2012
Price-control framework that the secretarial audit names as specifically applicable to the company.

Regulatory dependencies

5 verified
DPCO price controls on domestic medicines
Expansion of the list of price-controlled medicines would reduce domestic revenue and margins. Interpretation: a larger controlled list lowers domestic revenue and margin.
US generic pricing erosion
Continued price erosion in US generics compresses margins on established products. Interpretation: a fall in US prices lowers margin on older molecules, which is why the company moves toward complex and niche products.
cGMP compliance and market access
Non-compliance can cause import alerts, warning letters, recalls or restricted access. Interpretation: this would cut revenue in the affected market and raise costs for recalls.
2 more statements
Evolving international regulation and tariffs
Non-compliance with changing international rules can bring fines, sanctions or loss of market access. The company runs scenario planning for tariff and sanctions contingencies.
Tariff and sanctions contingencies
The company plans against tariff and sanctions changes. The excerpt does not give the tariff rate or effect.

Sensitivities

6 verified
Indian Rupee exchange rate
Direction: a stronger or weaker rupee changes the value of foreign-currency assets and liabilities, which moves profit and equity. The table reports the 10% effect by currency, with USD at ₹481.3 million before tax at 31 March 2025.
Interest rates on variable-rate borrowings
Direction: higher rates raise interest cost on variable-rate liabilities, which were ₹3,208.8 million at 31 March 2026. The 5% sensitivity is ₹7.3 million.
Mutual fund price risk
Direction: a rise in mutual fund prices raises profit and a fall lowers it. Mutual fund holdings were ₹912.5 million at 31 March 2026, down from ₹5,017.4 million.
3 more statements
Climate and weather
Direction: severe weather can disrupt operations, so events lower output and raise costs. The excerpt states the risk is expected to grow in frequency and intensity.
Single-facility concentration
Direction: an outage at the Sikkim facility would disrupt continuity and lower output. The excerpt names Sikkim as the example.
Pricing pressure in Southeast Asia
Direction: pricing pressure and launch delays in the Philippines lower revenue in that market. The company says corrective action is under way.

Cost inputs

5 verified
Raw material consumed
Largest cost of materials in the standalone note. FY2025 ₹23,623.4 million; FY2024 ₹22,059.6 million. Supplier mix is not stated in the excerpt.
Packing material consumed
Packaging input in the cost of materials. FY2025 ₹5,854.3 million; FY2024 ₹5,439.7 million.
Processing charges
Outsourced processing cost. FY2026 ₹993.7 million; FY2025 ₹600.3 million. Interpretation: this reflects use of outside manufacturing partners, which the company says it is expanding.
2 more statements
Licence, registration and technology fees
Fees paid for licences and technology. FY2026 ₹1,578.1 million; FY2025 ₹945.2 million.
Salaries, wages and bonus
Largest employee cost in the FY2025 standalone note: ₹15,937.9 million, against ₹14,438.9 million in FY2024.

Geographies

6 verified
India
Manufacturing base for the company, with 18 plants in India. Domestic revenue is shown in the segment note.
United States
Second-largest market by size, per the company. The company says the US plays a more measured role in its strategy, and US sales fell 10.4% in FY2025.
International sales share (29.8%)
Share of total sales from international operations in FY2025. Interpretation: the excerpt does not say whether the US is included in this share.
3 more statements
Key non-US markets
Named as key markets outside India and the US. The company states it is expanding into newer international markets.
Commonwealth of Independent States led by Kazakhstan
Emerging market in which the company's branded portfolio depth is the stated driver.
Exports as share of turnover
Export contribution to total turnover stated as 28% in this filing. Interpretation: chunk 30 states 27.32%, so the two filings differ.
Each statement is checked word for word against the FY2026 annual report; the passages are in the app.

What changed recently?

Q1 FY2027 results filed (14 Aug 2026).

Change log

8 entries · newest first
  1. Results filedQ1 FY2027 results filed.
  2. Corporate actionDividend - Rs 10 Per Share.
  3. Results filedQ4 FY2026 results filed.
  4. Corporate actionInterim Dividend - Rs 43 Per Share.
  5. Results filedQ3 FY2026 results filed.
  6. Results filedQ2 FY2026 results filed.
  7. Results filedQ1 FY2026 results filed.
  8. Corporate actionDividend - Rs 8 Per Share.
Get alerts →Sign in to be told when any of these change.

What this page does not tell you

What could not be judged, and why. Never empty.
  • Models not runFair value, EPV, Graham number, Graham value, Lynch, Owner earnings: no valuation stored.
  • FlagsCAUTION on 30 of 30 flags judged; 3 red.
  • Data gapsPEG (vendor), Business quality: not available yet.

What this page rests on

✓10 years of annual statements, through FY2026 (Mar-26)✓10 quarters of results✓130 months of month-end prices, adjusted for bonuses and splits○no valuation of ours yet✓business-model card FY2026 · 49 verified

Questions people ask

What is Alkem Laboratories's share price today?

Alkem Laboratories last traded at ₹5,205.00 on the NSE, as of 12 Oct 2026, 11:00 pm IST, down 1.4% on the day, down 3.9% over a year. Its 52-week range is ₹5,051 to ₹5,934. The live price is in the app.

What is Alkem Laboratories's market cap?

Alkem Laboratories's market capitalisation is about ₹63,118 crore: what it would cost to buy every share at today's price. That makes it the 67th largest mid cap company we cover.

Is Alkem Laboratories Ltd a large cap, mid cap or small cap?

Alkem Laboratories Ltd (ALKEM) is a mid cap company in AMFI's classification for Jan-Jun 2026. SEBI's buckets go by rank on six-month average market capitalisation: the top 100 are large caps, 101 to 250 mid caps, the rest small caps.

What is Alkem Laboratories Ltd's P/E ratio?

29.26, vs peers 39.3 · 4th of 23. Price divided by last year's earnings per share: how many years of today's profit you pay for.

Is Alkem Laboratories Ltd overvalued?

Cheap, with low confidence: no valuation within 120 days; P/E 29.3 vs peers 39.3 (4th of 23); P/B 4.5 vs peers 5.6 (11th of 25). Cheap for a reason: A negative 5-year return.

How does Alkem Laboratories Ltd make money?

Alkem Laboratories Limited sells pharmaceutical products, including chronic, specialty, OTC and generic lines, to pharmaceutical firms, distributors, wholesalers, pharmacy chains and hospitals in India, the US and more than 40 other countries. Revenue is recognised net of discounts, schemes, chargebacks, rebates and returns, and the filings report that dealers and distributors account for most sales.

Who are Alkem Laboratories Ltd's peers?

Compared with 24 Pharmaceuticals: Torrent Pharmaceuticals Ltd, Zydus Lifesciences Ltd, Laurus Labs Ltd, Cipla Ltd, Dr Reddys Laboratories Ltd and 19 more. The app shows how they compare on every figure.

Is this investment advice?

No. Valarth is a research and learning tool and is not a SEBI-registered investment adviser or research analyst. The figures come from the company's filings and the exchanges; what to do with them is your call.

How did Alkem Laboratories do last quarter?

Alkem Laboratories reported revenue of ₹3,740 Cr, up 13.5% on a year earlier and a net profit of ₹521 Cr, up 6.2% in the Jun 2026 quarter.

Who owns Alkem Laboratories?

Alkem Laboratories is held by promoters 49.7%, foreign institutions 10.4%, domestic institutions 22.6%.

Does Alkem Laboratories pay a dividend?

Yes. Alkem Laboratories's dividend yield is 1.00% at the latest price; the last payout was ₹10.00 a share, ex-dividend 7 Aug 2026.

What do analysts say about Alkem Laboratories?

20 analysts cover Alkem Laboratories, and the consensus is buy. A consensus is a count of opinions, not a forecast; read it beside the numbers.

Everything on Alkem Laboratories, and 6,621 other companies, with 212 filters and the full peer tables

See Alkem Laboratories in the app →See pricing